Bio Thera files for China approval of Actemra biosimilar

10 November 2021
china_regulator_cnmpa_big

Chinese biotech Bio Thera Solutions (688177 SH) has filed a new drug application (NDA) with China’s National Medical Products Administration (NMPA) to gain approval of what would be the country's first biosimilar of Actemra (tocilizumab).

The biosimilar was in-licensed from US biotech Biogen (Nasdaq: BIIB) in April. Originated by Swiss pharma giant Roche (ROG: SIX), Actemra was approved in China in 2016 to treat rheumatoid arthritis and other diseases, such as systemic juvenile idiopathic arthritis.

Global sales Actemra/RoActemra rose 30% year-on-year to 2.69 billion Swiss francs ($2.95 billion) for the first nine months of the current year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars